文献速递中医内科中药与中成药合理使用

中药治疗轻中度COVID-19有效性与安全性的系统评价与Meta分析

Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials and observational studies.
PubMed 文献 · Front Pharmacol · 2022-09-07

该系统评价纳入35项随机对照试验和24项观察性研究,共16,580例轻中度COVID-19患者,评估中药对比常规支持治疗的疗效与安全性。证据确定性为极低至低,但多数效应估计方向一致,显示中药在降低重症转化率、死亡率、缩短症状缓解时间、住院时间和病毒清除时间方面有获益,且未发现严重不良反应。

要点

  • 中药可降低轻中度COVID-19患者的重症转化率和死亡率,但证据确定性为极低至低。
  • 中药可缩短症状缓解时间、住院时间和病毒清除时间,并提高核酸转阴率。
  • 中药安全性与常规支持治疗相当,未发现严重不良反应。

核心结论

  • 中药治疗轻中度COVID-19患者显示出获益证据,安全性 profile 与常规支持治疗相当。
  • 仍需更严格设计的临床试验和机制研究进一步证实当前发现。

研究设计与样本

  • 系统评价与Meta分析,检索9个数据库至2022年3月19日。
  • 纳入35项随机对照试验和24项观察性研究,共16,580例轻中度COVID-19患者。
  • 采用GRADE系统评估证据确定性,证据确定性为极低至低。

主要发现

  • 与常规支持治疗相比,中药降低重症转化率:RCTs绝对风险差为每1000例患者减少99例,观察性研究为每1000例减少131例(基线风险16.52%)。
  • 中药降低死亡率:RCTs和观察性研究的绝对风险差均为每1000例患者减少3例(基线风险0.40%)。
  • 中药缩短症状缓解时间:RCTs为3.35天,观察性研究为2.94天。
  • 中药缩短住院时间:RCTs为2.36天,观察性研究为2.12天;缩短病毒清除时间:RCTs为2.64天,观察性研究为4.46天。
  • 中药提高核酸转阴率:观察性研究绝对风险差为每1000例患者增加73例(基线风险16.30%)。

关键数值与推荐

  • 重症转化率基线风险16.52%,死亡率基线风险0.40%,核酸转阴率基线风险16.30%。
  • 证据确定性为极低至低(GRADE评估)。

临床怎么用

  • 在常规支持治疗基础上,可考虑联合中药治疗轻中度COVID-19患者以降低重症转化风险并加速康复。
  • 需向患者说明现有证据确定性较低,中药获益方向一致但强度有限。

局限性

  • 纳入研究的证据确定性为极低至低,主要结论需谨慎解读。
  • 多数效应估计来自随机对照试验和观察性研究,但观察性研究存在固有偏倚风险。
  • 仍需更严格设计的临床试验和机制研究进一步证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The coronavirus disease 2019 (COVID-19) is still a pandemic globally, about 80% of patients infected with COVID-19 were mild and moderate. Chinese herbal medicine (CHM) has played a positive role in the treatment of COVID-19, with a certain number of primary studies focused on CHM in managing COVID-19 published. This study aims to systematically review the currently published randomized controlled trials (RCTs) and observational studies (OBs), and summarize the effectiveness and safety of CHM in the treatment of mild/moderate COVID-19 patients. Methods: We searched 9 databases up to 19 March 2022. Pairs of reviewers independently screened literature, extracted data and assessed risk of bias. For overall effect, we calculated the absolute risk difference (ARD) of weighted averages of different estimates, and certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) system. Results: We included 35 RCTs and 24 OBs enrolling 16,580 mild/moderate patients. The certainty of evidence was very low to low. Compared with usual supportive treatments, most effect estimates of CHM treatments were consistent in direction. CHMs presented significant benefits in reducing rate of conversion to severe cases (ARD = 99 less per 1000 patients in RCTs and 131 less per 1000 patients in OBs, baseline risk: 16.52%) and mortality (ARD = 3 less per 1000 patients in RCTs and OBs, baseline risk: 0.40%); shortening time to symptom resolution (3.35 days in RCTs and 2.94 days in OBs), length of hospital stay (2.36 days in RCTs and 2.12 days in OBs) and time to viral clearance (2.64 days in RCTs and 4.46 days in OBs); increasing rate of nucleic acid conversion (ARD = 73 more per 1000 patients in OBs, baseline risk: 16.30%). No serious adverse reactions were found and the differences between CHM and usual supportive care were insignificant. Conclusion: Encouraging evidence showed that CHMs were beneficial in treating mild or moderate patients. CHMs have been proved to possess a safety profile that is comparable to that of usual supportive treatment alone. More rigorously designed clinical trials and mechanism studies are still warranted to further confirm the present findings.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhu H, Li M, Tian C, et al. Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials and observational studies. Front Pharmacol. 2022. PMID: 36160412. doi:10.3389/fphar.2022.988237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。